Adaptimmune Therapeutics plc
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2014 | — | $3.0M | $51.2M |
| FY2015 | — | $259.0M | $229.0M |
| FY2016 | — | $166.1M | $158.8M |
| FY2017 | — | $203.0M | $84.0M |
| FY2018 | — | $246.9M | $68.4M |
| FY2019 | — | $123.6M | $50.4M |
| FY2020 | — | $341.2M | $56.9M |
| FY2021 | — | $206.0M | $149.9M |
| FY2022 | — | $81.9M | $108.0M |
| FY2023 | — | $39.5M | $144.0M |
| FY2024 | $50.2M | $11.8M | $91.1M |